Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.55 |
| ▸ | F2 | P00734 | 14/20 | 0.54 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.51 |
| ▸ | F9 | P00740 | 1/20 | 0.51 |
| ▸ | F10 | P00742 | 1/20 | 0.51 |
| ▸ | PLAT | P00750 | 1/20 | 0.51 |
| ▸ | F11 | P03951 | 1/20 | 0.51 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.51 |
| ▸ | F7 | P08709 | 1/20 | 0.51 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.51 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28842114 | 1.00 | ALDH1A1 (0.60) | ALDH1A1CYP3A4F2PRSS1F9 | |
| SCHEMBL6078170 | 0.94 | ALDH1A1 (0.62) | ALDH1A1CYP3A4F2PRSS1F9 | |
| SCHEMBL29880365 | 0.93 | ALDH1A1 (0.59) | ALDH1A1CYP3A4F2PRSS1F9 | |
| SCHEMBL6079282 | 0.92 | ALDH1A1 (0.64) | ALDH1A1CYP3A4F2PRSS1F9 | |
| SCHEMBL6077964 | 0.91 | ALDH1A1 (0.62) | ALDH1A1CYP3A4F2PRSS1F9 | |
| SCHEMBL6919708 | 0.90 | CYP3A4 (0.58) | ALDH1A1CYP3A4F2PRSS1F9 | |
| SCHEMBL7507374 | 0.89 | ALDH1A1 (0.56) | ALDH1A1CYP3A4F2PRSS1F9 | |
| SCHEMBL6078172 | 0.89 | ALDH1A1 (0.57) | ALDH1A1CYP3A4F2PRSS1F9 | |
| SCHEMBL6078165 | 0.89 | ALDH1A1 (0.57) | ALDH1A1CYP3A4F2PRSS1F9 | |
| SCHEMBL23478726 | 0.87 | F2 (0.50) | ALDH1A1CYP3A4F2PRSS1F9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486278-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2025-12-02 | — | — | US | disclosed |
| US-20240092788-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2024-03-21 | — | — | US | disclosed |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-11-07 | — | — | US | disclosed |
| CN-115103709-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2022-09-23 | — | — | CN | disclosed |
| US-20210171531-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2021-06-10 | — | — | US | disclosed |
| WO-2021113682-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |
| US-7144899-B2 | Thrombin inhibitors | MERCK & CO., INC. (US) | 2006-12-05 | — | — | US | disclosed |
| US-20040073025-A1 | Thrombin inhibitors | MERCK SHARP & DOHME CORP. | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171531-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | ALDH1A1 4709/4885CYP3A4 4706/4885F2 4221/4885 |
| US-12486278-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | ALDH1A1 4709/4885CYP3A4 4706/4885F2 4221/4885 |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | ALDH1A1 4709/4885CYP3A4 4706/4885F2 4221/4885 |
| US-20240092788-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | ALDH1A1 4709/4885CYP3A4 4706/4885F2 4221/4885 |
| US-20040073025-A1 | Thrombin inhibitors | F2, F11, F10 | ALDH1A1 2954/4885CYP3A4 2153/4885F2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.